Summary: Extended half-life proteins (EHL) are increasingly used in clinical practice, but there is no standardized approach to sampling, interpretation and implementation of pharmacokinetics (PK) data to maximize treatment benefit. The goal of EHL treatment is to attain a trough level sufficient to protect against spontaneous bleeds and reduce infusion frequency and limitations on individual activity and lifestyle. Performing classical PK assessments requires multiple blood samples, which is burdensome for patients and providers. Herein we review a population pharmacokinetic (popPK) approach to estimate individual PK parameters to transition patients from standard half-life (SHL) to EHL concentrates. We propose that a minimum of two to four post-infusion samples is sufficient to estimate individual PK profiles, with sufficient certainty to maintain factor levels above 1% and achieve bleed-free lifestyles. We also survey current PK use in patients transitioning to EHL, review key PK parameters and popPK models, and recommend an approach to using PK in patients initiating or switching to EHL.

Additional Metadata
Persistent URL dx.doi.org/10.1111/jth.14153, hdl.handle.net/1765/114180
Journal Journal of Thrombosis and Haemostasis
Citation
Ragni, M, Croteau, S.E. (S. E.), Morfini, M, Cnossen, M.H. (M. H.), & Iorio, A. (A.). (2018). Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 16(7), 1437–1441. doi:10.1111/jth.14153